| Drug Name: | Pyrazinamide (98-96-4) |
|---|---|
| PubChem ID: | 1046 |
| SMILES: | C1=CN=C(C=N1)C(=O)N |
| InchiKey: | IPEHBUMCGVEMRF-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antitubercular Agents |
| Molecular Weight (dalton) | : | 123.115 |
| LogP | : | -0.4245 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 68.87 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Allopurinol (315-30-0) | Hyperuricaemia | Antagonistic | pyrazinamide is hydrolysed in the body to pyrazinoic acid, which appears to be responsible for the hyperuricaemic effect of pyrazinamide. Pyrazinoic acid is oxidised by the enzyme xanthine oxidase to 5-hydroxypyrazoic acid. Since allopurinol is an inhibitor of xanthine oxidase, its presence increases pyrazinoic acid concentrations | Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention |
| Probenecid (57-66-9) | Diminished Uricosuric Effects Of Probenecid | Antagonistic | pyrazinamide additionally decreases the metabolism of the probenecid and prolongs its uricosuric effects | Studies of hyperuricemia produced by pyrazinamide |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category